Abstract:MicroRNAs (miRNAs) regulate approximately one-third of all human genes. The dysregulation of miRNAs has been implicated in the development of numerous human diseases, including cancers. In our investigation focusing on altering specific miRNA expression in human pancreatic cancer cells, we encountered an interesting finding. While two expression vector designs effectively enhanced miR-708 levels, they were unable to elevate mature forms of miR-29b, -1290, -2467, and -6831 in pancreatic cancer cell lines. This finding was also observed in a panel of other non-pancreatic cancer cell lines, suggesting that miRNA processing efficiency was cell line specific. Using a step-by-step approach in each step of miRNA processing, we ruled out alternative strand selection by the RISC complex and transcriptional interference at the primary miRNA (pri-miRNA) level. DROSHA processing and pri-miRNA export from the nucleus also appeared to be occurring normally. We observed precursor (pre-miRNA) accumulation only in cell lines where mature miRNA expression was not achieved, suggesting that the block was occurring at the pre-miRNA stage. To further confirm this, synthetic pre-miRNA mimics that bypass DICER processing were processed into mature miRNAs in all cases. This study has demonstrated the distinct behaviours of different miRNAs with the same vector in the same cell line, the same miRNA between the two vector designs, and with the same miRNA across different cell lines. We identified a stable vector pre-miRNA processing block. Our findings on the structural and sequence differences between successful and non-successful vector designs could help to inform future chimeric miRNA design strategies and act as a guide to other researchers on the intricate processing dynamics that can impact vector efficiency. Our research confirms the potential of miRNA mimics to surmount some of these complexities.

Let the Cells Do the Work: Production of Novel Recombinant Pre‐mirnas in E. Coli As Therapeutic Agents

Rapid Production of Novel Pre-Microrna Agent Hsa-Mir-27b in Escherichia Coli Using Recombinant RNA Technology for Functional Studies in Mammalian Cells.

Bioengineering Novel Chimeric Microrna-34A for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.

Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia Coli is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy

A General Approach to High-Yield Biosynthesis of Chimeric Rnas Bearing Various Types of Functional Small Rnas for Broad Applications

MicroRNA-based Therapeutic Technologies

Progress in Microrna Delivery

TALEN/CRISPR-mediated Engineering of a Promoterless Anti-Viral RNAi Hairpin into an Endogenous Mirna Locus

Recent developments in miRNA based recombinant protein expression in CHO

A Simplified System for the Effective Expression and Delivery of Functional Mature Micrornas in Mammalian Cells

miRNA- and Cell Line-Specific Constraints on Precursor miRNA Processing of Stably Transfected Pancreatic Cancer and Other Mammalian Cells

Bioengineered Mir-27B-3p and Mir-328-3p Modulate Drug Metabolism and Disposition Via the Regulation of Target ADME Gene Expression.

Therapeutic MicroRNA Strategies in Human Cancer

Recent progress in microRNA-based delivery systems for the treatment of human disease

Transcripts for Combined Synthetic Microrna and Gene Delivery

Primer Extension-Based Method for the Generation of a Sirna/mirna Expression Vector.

Discovery of microsized RNA-derived RNAs and proteins in human cells

The Effect of microRNA on the Production of Recombinant Protein in CHO Cells and its Mechanism

Methods for Using Small Non-Coding RNAs to Improve Recombinant Protein Expression in Mammalian Cells

Adenovirus-mediated Shrnas for Co-Repression of Mir-221 and Mir-222 Expression and Function in Glioblastoma Cells.